Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-EGF in Hormone Resistant Prostate Cancer
NCT00061126Phase 2Completed
- Sponsor
- Abgenix
- Start
- Apr 2003
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in prostate cancer (PCa), sponsored by Abgenix. Primary endpoints: Safety and Efficacy. Started Apr 2003; status: completed.
02
Drugs
panitumumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00061126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061126.